The recombinant protein market involves production of therapeutic proteins and drugs using recombinant DNA technology and cell culture. Recombinant proteins find wide applications in biopharmaceuticals development for treating conditions such as diabetes, cancer, arthritis and cardiovascular diseases. They serve as alternatives to proteins isolated from animal tissues in drug formulation. The recombinant protein technology helps in mass production of consistent and safe human proteins of high purity levels.
The Global recombinant protein market is estimated to be valued at US$ 3607.34 Bn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Recombinant Protein Market Demand are Merck KGaA, Allergan plc ( A subsidiary of AbbVie Inc.), Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical (A subsidiary of Alcon Management S. A) and Mylan N.V (A subsidiary of Viatris Inc.). These players are involved in developing and marketing recombinant proteins and gene therapies for various therapeutic areas worldwide.
The growing demand for biopharmaceuticals is driving the recombinant protein market. Biologics have revolutionized treatment of various chronic diseases. With rising prevalence of non-communicable diseases, demand for effective and targeted biologics is increasing significantly. This is augmenting demand for recombinant proteins which are used extensively in development and production of biopharmaceutical drugs and therapies.
Technological advancements are further fueling the recombinant protein market growth. Companies are focusing on developing advanced production platforms like mammalian, yeast, insect and plant cell expression systems for large scale, cost-effective manufacturing of recombinant proteins. Automation of downstream processing is also helping in accelerating production while maintaining high quality standards.
Market Trends
Increasing Demand for Biosimilars - With patent expiries of major biologics, biosimilar drugs are emerging as alternative treatment options. This is creating strong demand for recombinant proteins which are used extensively during development of biosimilars.
Rising R&D into Gene Therapies - More pharmaceutical players are actively conducting research on development of novel recombinant vectors and gene therapies for genetic disorders. This will aid recombinant protein market owing to their use as gene delivery tools.
Market Opportunities
High Growth Potential in Emerging Markets - Markets in Asia Pacific,Latin America, Middle East and Africa are expected to provide lucrative opportunities for recombinant protein suppliers due to improving healthcare infrastructure and increasing healthcare spending in these regions.
Technological Advancements in Expression Systems - Continuous technological improvements in expression systems for enhanced production yields will create new revenue pockets over the coming years. This includes development of new prokaryotic and eukaryotic cell lines.
Impact of COVID-19 on Recombinant Protein Market Growth
The COVID-19 pandemic has significantly impacted the growth of the recombinant protein market. During the initial stages of the pandemic, many countries went under complete lockdown which disrupted the supply chain and manufacturing operations. This led to a shortage in the supply of recombinant proteins, affecting the research and development activities carried out in the pharmaceutical and biotechnology sectors. However, with the pandemic increasing the focus on vaccine development and therapeutics, the demand for recombinant proteins saw huge growth. Researchers relied heavily on recombinant proteins to understand virus-host interactions and screen potential drug targets during drug discovery processes. Additionally, the development of COVID-19 vaccines which utilised recombinant protein technology further drove market growth during the pandemic. Although supply chains were impacted initially, manufacturers collaborated to ramp up production capacities to meet the rising demand from researchers and vaccine developers. In the forecast period, government funding for pandemic preparedness initiatives and increase in R&D investments from pharma companies are expected to sustain the high growth trajectory of the recombinant protein market in the post-COVID scenario. Adopting advanced production technologies, building strategic partnerships and ensuring redundancy in global supply networks will be the key strategies for companies to remain resilient against future disruptions.
The United States accounts for the largest share of the recombinant protein market in terms of value. This is attributed to presence of numerous global pharmaceutical and biotechnology companies investing heavily in rDNA research. Additionally, the region has strong government support for life science research evidenced through high funding flows from national institutes. Europe follows the United States in terms of market concentration owing to robust pharmaceutical manufacturing base and increasing focus on personalized medicine adopting new biologic modalities. However, Asia Pacific region is projected to become the fastest growing market for recombinant proteins during the forecast period. This is backed by improved regulatory frameworks, low production costs and expanding biosimilar manufacturing capabilities in China and India. Additionally, growing public and private investments in biotechnology and emerging new markets such as South Korea, Japan and Australia will further boost recombinant protein adoption in the Asia Pacific region in coming years.
Geographical regions where Recombinant Protein Market is concentrated in terms of value:
United States
- Presence of numerous global pharmaceutical and biotechnology companies investing heavily in rDNA research
- Strong government support for life science research evidenced through high funding flows from national institutes
Fastest growing region for Recombinant Protein Market:
Asia Pacific region
- Improved regulatory frameworks, low production costs and expanding biosimilar manufacturing capabilities in China and India
- Growing public and private investments in biotechnology and emerging new markets such as South Korea, Japan and Australia
Get more insights on Recombinant Protein Market
UpMarketResearch published an exclusive report on “Recombinant Protein market” delivering key insights and providing a competitive advantage to clients through a detailed report.
The report contains 116 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.
Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
The report contains basic, secondary and advanced information pertaining to the Recombinant Protein global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2018 - 2025.
The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on.
For more information on this report, please visit: https://www.upmarketresearch.com/home/enquiry_before_buying/24735 The following manufacturers are covered in this report:R SystemsProSpecThermo Fisher ScientificGenScriptFiberCell SystemsApplied Biological Materials IncPeprotechChimerigenOrigeneNOVUSAbnova Recombinant Protein Production by RegionNorth AmericaAsia-PacificEuropeCentral & South AmericaMiddle East & Africa Get Best Discount On This Report @ https://www.upmarketresearch.com/home/request_for_discount/24735 Global Recombinant Protein Market: Product Segment AnalysisMolecular CloningPolymerase Chain Reaction Recombinant Protein Breakdown Data by ApplicationPharmaceuticalsBiological TechnologyOther Get Free Exclusive PDF Sample Copy of This Report @ https://www.upmarketresearch.com/home/requested_sample/24735 The report categorizes the market into segments by companies, end-use, type and potential regions.
